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ABSTRACT27 
Objectives – GBA1 mutations are a frequent risk factor for Parkinson disease (PD).  Aim of this study is to 28 
evaluate clinical features in a group of GBA1 mutation positive individuals over a 6-year follow-up.  29 
Methods – This is a longitudinal study on a cohort of GBA1 positive carriers. We enrolled 31 Gaucher 30 
Disease type 1 patients (GD), 29 GBA1 heterozygous carriers (Het GBA group) and 30 controls (HC) at 31 
baseline and followed them for 6-years. We assessed baseline motor and non-motor signs of PD in all 32 
subjects using clinical questionnaires and scales (reduced UMSARS, MoCA, UPSIT, RBDsq, MDS-UPDRS III 33 
and BDI). We repeated these at the 6-year follow-up alongside venous blood sampling for measurement of 34 
glucocerebrosidase enzymatic activity (GCase). We explored whether the GCase activity level was altered in 35 
leukocytes of these subjects and how it was related to development of PD.36 
Results: We observed a significant worsening in UMSARS, RBDsq, MDS-UPDRS III and BDI scores at the 6-37 
year follow-up compared to baseline in both the GD and Het GBA groups. Intergroup comparisons showed 38 
that GD subjects had significantly worse scores in UPSIT, UMSARS, MoCA and MDS-UPDRS III than HC, while 39 
Het GBA displayed worse outcomes in UPSIT and MDS-UPDRS III compared to HC. In GBA1 mutation 40 
positive individuals (Het GBA and GD), an UPSIT score of 23 at baseline was correlated with worse outcome 41 
at 6 years in UPSIT, MoCA, MDS-UPDRS III and BDI.  42 
Conclusion: in this 6-year long longitudinal study, GBA1 mutation positive subjects showed a worsening in 43 
motor and non-motor prodromal PD features.  44 
3 
INTRODUCTION 45 
Significant advances have been made in recent years in understanding the genetic contribution to 46 
Parkinson disease (PD). Glucocerebrosidase 1 (GBA1) mutations are considered the most important risk 47 
factor for PD[1]. GBA1 encodes for the lysosomal enzyme glucocerebrosidase (GCase) and biallelic  48 
mutations in this gene cause Gaucher disease (GD)[2]. The observation that type 1 GD patients exhibit a 49 
high incidence of PD was made more than 20 years ago [3,4]. Studies have reported a significantly higher 50 
frequency of heterozygous GBA1 mutations in PD patients, suggesting a causative role of GBA1 in the 51 
pathogenesis of the disease[5–9]. Additionally, numerous genome wide association studies confirmed the 52 
strong association of GBA1 with PD, identifying an Odds Ratio higher than 5 for developing PD [1,10–13]. 53 
Recent reports have also shown that decreased GCase activity in the brain of sporadic PD are linked with 54 
increased a-synuclein levels[14,15], suggesting a role for GCase in the pathogenesis of ‘idiopathic’ PD. 55 
The identification of the GBA1 link has therapeutic implications, as enzyme replacement and substrate 56 
reduction therapies are regularly employed to treat GD [16] and it is possible that the same strategies could 57 
be used to slow PD progression. Furthermore, numerous studies are investigating compounds that directly 58 
interact with GCase to treat GBA1 mutated PD patients [17]. 59 
Only about 30% of individuals with a GBA1 mutation develop PD [18] and so a better risk stratification is 60 
still needed to identify those at greater risk and to select participants for clinical trials for disease modifying 61 
therapy. In 2012, our group published a study on the assessment of a cohort of neurologically 62 
asymptomatic GBA1 mutation carriers and showed that cognitive, olfactory and parkinsonian  motor signs 63 
were worse in not only homozygous, but also in heterozygous GBA1 mutation carriers compared to 64 
controls[19]. A 2-year follow up study confirmed these findings and their progression[20]. A separate paper 65 
will report the evolution of prodromal features over 4-5 years. The identification of clinical and biochemical 66 
markers is therefore important to phenotype GBA1 mutation positive individuals potentially at risk of 67 
developing PD.  68 
In this study, we assessed our cohort focusing on how parkinsonian  clinical markers evolved over a 6-year 69 
observation period and whether baseline findings were able to predict a worsening of these signs over 70 
4 
time. We also explored whether the GCase activity level is altered in peripheral blood leukocytes of these 71 
subjects and how it is related to PD development.  72 
73 
MATERIALS AND METHODS 74 
75 
Participants 76 
This is a longitudinal study over 6 years involving type 1 GD patients, heterozygous GBA1 mutation carriers 77 
(Het GBA) and genetically unrelated controls (HC) that started in 2010[19]. The GD patients were recruited 78 
from the Lysosomal Storage Disorder Unit at the Royal Free London NHS Foundation Trust. Potential Het 79 
GBA subjects were identified among the family members of each GD patient. At baseline, HC were matched 80 
to GD patients and Het GBA for age, sex, and ethnicity. Controls had no neurological disease or systemic 81 
disease that could impair motor function. Demographic participant characteristics at baseline and 2 years-82 
timepoint are reported in Supplementary Table 1. Exclusion criteria were the presence of neurological 83 
signs or cognitive impairment at baseline. All the participants from the original cohort[19] were invited to 84 
take part in the 6-year follow-up assessment. From the 90 subjects at baseline, 63 completed the follow-up. 85 
The main reasons for dropout (14 HC and 13 Het GBA subjects, respectively) were death (5 HC and 4 Het 86 
GBA), failure to contact (3 HC and 2 Het GBA)  and withdrawal of consent (6 HC and 7 Het GBA) . The 87 
protocol was approved by the North-West London Research Ethics Committee (reference number 10/ 88 
H0720/21) and all subjects gave written consent before being enrolled in the study. 89 
90 
Follow-up evaluation 91 
We examined all subjects with a structured clinical evaluation that included: motor and cognitive 92 
performance, olfactory function, REM sleep behavior disorder (RBD), autonomic dysfunction and 93 
depression. Motor performances were assessed by the Movement Disorders Society Unified Parkinson’s 94 
Disease Rating Scale motor subscale (MDS-UPDRS part III)[21], olfactory function by the University of 95 
Pennsylvania Smell Identification Test (UPSIT), cognitive function by the Montreal Cognitive assessment 96 
(MoCA), RBD with the RBD Questionnaire (RBDsq), depression by the Beck’s Depression Inventory version II 97 
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(BDI) and autonomic dysfunction by a subscale of the Unified Multiple System Atrophy Rating Scale 98 
(UMSARS) that included questions 9, 10, 11 and 12 of the original scale. In accordance with the references 99 
listed below, the following cut-offs were used: MoCA score less than 26 for cognitive impairment[22], 100 
UPSIT score less than or equal to 23 for severe microsmia [23,24], BDI greater than 9 for mild depression 101 
[25], RBDsq greater than 4 for RBD[26]. For the sub-items of the MDS-UPDRS part III we used a cut-off of 102 
greater or equal to 1. Two unblinded evaluators (MA and MT) independently examined all the subjects in 103 
order to avoid possible bias on the clinical scores.  104 
105 
Genotyping and GCase activity assay  106 
All participants were genotyped in order to confirm their GBA1 mutation status using Sanger sequencing of 107 
the GBA1 gene[27]. At the 6-year follow-up, all subjects underwent a blood test to measure the GCase 108 
activity in peripheral blood leucocytes according to commonly used methods [28,29]. The final result is 109 
reported as nmol of substrate per hour per microgram of proteins. In GD participants that were taking 110 
enzyme replacement therapy blood samples were collected just prior to the infusion (infusions were 111 
carried out every 2 weeks), in order to have a better sense of the residual enzymatic activity in each 112 
participant [30]. 113 
114 
Statistical Analysis 115 
Statistical analysis was performed using “Stata” version v.13.0 (StataCorp, Texas). For age and years of 116 
education, differences between groups were analyzed using ANOVA (analyses of variance) with groups as 117 
the independent factors. For sex, difference between groups was tested with the Chi-square test. To assess 118 
within groups differences (“baseline” vs “6 years follow-up”) in each group separately, Wilcoxon matched-119 
pairs signed-rank test for paired samples was used, with a false discovery rate of 5% (Benjamini-Hochberg 120 
procedure)[31]. For this analysis, only participants that completed the 6 years follow-up were included. The 121 
longitudinal clinical data over 6 years were analysed using a linear mixed effect model with groups as 122 
independent variable and age, sex and years of education (when applicable) as covariates. The p-values 123 
refer to the fixed coefficients for each group compared to the others. A false discovery rate of 5% was set 124 
6 
(Benjamini-Hochberg procedure). For this analysis, all participants were included, even if they dropped out 125 
before the 6-years timepoint. 126 
In an exploratory analysis, we investigated whether baseline scores may be a predictor for worsening of 127 
motor and non-motor performances over time.  Among all clinical markers at baseline, participants with  128 
severe microsmia (UPSIT <=23)[23,24] showed a trend toward deterioration of motor and non-motor 129 
symptoms. We used a two-sample Fisherman-Pitman randomization test to determine whether this trend 130 
was statistically significant. A false discovery rate of 5% was set (Benjamini-Hochberg procedure)[31]. 131 
Statistical analysis for GCase activity was performed by Kruskal-Wallis test followed by Dunn's Pairwise test 132 
for group comparison. The relationship between GCase activity and clinical parameters was performed by 133 
linear regression for UPSIT score and censored linear regression for MoCA, RBDsq, reduced UMSARS, MDS-134 
UPDRS III and BDI to avoid ceiling and bottom effects. To check for possible differences at baseline between 135 
dropouts and non-dropouts, we used the Mann-Whitney two-sample test. 136 
137 
RESULTS138 
Demographic characteristics of subjects that completed follow up are reported in Table 1. No significant 139 
differences in gender, age and years of education were found between groups (all p > 0.05). 63 participants 140 
completed the 6-year follow-up: 31 type I GD patients, 16 Het GBA carriers and 16 HC. After re-genotyping, 141 
we identified 1 new GD patient that was previously classified as Het GBA. No GBA1 mutation was identified 142 
in HC subjects in exons 1 to 11 of the GBA1 gene. The most frequent GBA1 mutation in the Het GBA group 143 
was N370S (8/16; 50 %), followed by L444P and V394L (both 2/16; 12.5%). For GD patients, N370S/L444P 144 
was the most common genotype (7/31; 22.6%), followed by N370S/N370S (3/31; 9.68%). Among the GD 145 
patients, 25 (81%) were receiving enzyme replacement therapy and 2 (7%) were receiving substrate 146 
reduction therapy. 147 
148 
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TAB.1 - Demographic characteristics of the 3 groups of subjects at 6-years  149 
Tot. HC Het GBA GD p-value 
N. subjects 63 16 16 31 -
Sex (F/M) 28/ 35 8 / 8 7 / 9 13/ 18 0.95
Age at 
baseline 
55.13    10.97 56.5   11.  59    9.02 52.39     11.13 0.12 
Years of 
education 
14.04  3.31 15.62    3.51 13.12     3.07 13.69    3.14 0.07 
Data are presented as mean + SD. Group comparison performed with one-way ANOVA for age and years of education, 150 
Fisher exact test was used for sex variable. 151 
152 
After 6 years of observation, 1 GD subject, age range 45-50 at baseline (real age not disclosed to protect 153 
the privacy of the subject), developed PD according to clinical diagnostic criteria[32]. At baseline  this 154 
subject did not show any neurological signs and all the evaluated clinical parameters were within normal 155 
range except for UPSIT score (20). At 6-year evaluation, subject showed resting tremor, bradykinesia and 156 
cognitive impairment with the following clinical scores: MOCA 19, UPSIT 9, BDI 36, MDS-UPDRS III  63 (off 157 
state), UMSARS 7, RBDsq 3.  158 
In the GD group, 5 subjects (16.1%) developed cognitive impairment,  4 subjects (12.9%) developed 159 
hyposmia , 8 subjects (25.8%) reported depression symptoms , 4 subjects (18.2%) had RBD disorders , 4 160 
subjects (12.9%) developed global bradykinesia, 2 subjects (6.5%) developed upper limbs resting tremor, 8 161 
subjects (25.8 %) developed abnormal posture, 6 subjects (19.4 %) developed postural instability, 10 162 
subjects (32.3 %) developed action tremor of hands, and 4 subjects (12.5 %) developed postural tremor of 163 
hands. In accordance with the same cut-offs, in the Het GBA group, 1 subject (6.3 %) developed cognitive 164 
impairment , 3 subjects (19%) developed hyposmia, 1 subject (6.3%) developed depression symptoms, 2 165 
subjects (13.3%) developed RBD disorders, 3 subjects (19 %) showed abnormal posture, 4 subjects  (25%) 166 
developed postural instability, 1 subject (6.3 %) developed action and postural tremor of hands. In the HC 167 
group, 2 subjects (12.5 %) developed cognitive impairment , 1 subject (6.3 %) developed hyposmia, 1 168 
subject (8.3%) developed RBD disorder, 3 subjects  (19 %) showed slightly stooped posture, 1 subject  169 
(6.3%) slightly postural instability, 2 subjects (12.5 %) developed action tremor of hands and 3 subjects 170 
(18.9 %) developed postural tremor of hands (Data are summarised in Table 2). Baseline clinical scores of 171 
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participants that dropped out at follow-up are reported in Supplementary Table 2. Of the subjects that 172 
showed parkinsonian features at baseline and at 2-years follow-up [19,20], 3 GD patients and 1 Het 173 
GBA subject remained clinically stable, 1 GD patient showed a worsening of parkinsonian 174 
motor features that were not yet sufficient for a diagnosis of PD and 1 Het GBA was lost at 175 
follow-up.176 
Table. 2 – Description of progression of clinical features after 6 years follow-up in the 3 groups of 177 
subjects 178 
HC Het GBA GD  
Cognitive impairment (MoCA <26) 2 (12.5%) 1 (6.3%) 5 (16.1%)
Hyposmia (Upsit cut-off <=23) 1 (6.3 %) 3 (19 %) 4 (12.9%)
Depression (BDI cut-off 10) - 1 (6.3 %) 8 (25.8 %)
RBD disorders (RBDsq 5)  1 (8.3 %) 2 (13.3 %) 4 (18.2%)
Global bradykinesia (MDS-UPDRS 
part III subscore >= 1)
- - 4 (12.9%)
Resting tremor (MDS-UPDRS part III 
subscore >= 1)
- - 2 (6.5%)
Abnormal posture (MDS-UPDRS
part III subscore >= 1)
3 (18.9 %) 3 (19 %) 8 (25.8 %)
Postural instability (MDS-UPDRS
part III subscore >= 1)
1 (6.3 %) 4 (25%) 6 (19.4 %)
Action tremor (MDS-UPDRS part III 
subscore >= 1) 
2 (12.5 %) 1 (6.3 %) 10 (32.3 %)
Postural tremor (MDS-UPDRS part 
III subscore >= 1) 
3 (18.9 %) 1 (6.3 %) 4 (12.9 %)
Clinically defined PD - - 1 (3.2 %)
Data are presented as number of cases and percentage of all subjects within group. Cut-off references are reported in 179 
the Methods section. 180 
181 
182 
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Evolution of clinical markers over 6 years 183 
Means and standard errors of the clinical scales for participants that completed the 6-year follow-up are 184 
reported in table 3 and figure 1. At 6 years, both the GD and Het GBA groups displayed a significant 185 
deterioration in the reduced UMSARS (p <0.001 and =0.001 respectively), RBDsq (p <0.001 and <0.001 186 
respectively), MDS-UPDRS III (p<0.001 and =0.010 respectively) and BDI (p =0.001 and =0.007 respectively) 187 
compared to baseline. Neither the GD nor Het GBA groups as a whole showed any significant worsening in 188 
the MoCA and UPSIT scores. The HC group displayed a significant worsening in UPSIT (p =0.013), UMSARS 189 
(p =0.004), BDI (0.031) compared to baseline, while the MoCA score showed a significant improvement (p 190 
=0.019).  191 
To compare longitudinal data between the three groups, we ran a mixed effect linear regression model. In 192 
this analysis, the GD group had significantly worse scores than HC in UPSIT (p 0.001), reduced UMSARS (p 193 
0.019), MoCA (p 0.006) and MDS-UPDRS III  (p 0.001), while the Het GBA group displayed worse outcomes 194 
than HC in UPSIT (p <0.001) and MDS-UPDRS III  (p =0.001). We observed the same trend of worse 195 
performance of GD and Het GBA compared to HC in RBDsq and BDI scores, although it did not reach 196 
statistical significance (Figure 1). Main findings are summarized in Table 3. Parameter estimates for the 197 
longitudinal models are reported in Supplementary Table 3.  198 
199 
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TAB. 3 – Evolution of clinical markers over 6 years and comparison between groups 200 
Data are reported as means ( standard errors).  201 
a Wilcoxon matched-pairs signed-rank test comparing baseline and 6-year follow-up scores within each group 202 
separately. A false discovery rate of 5% was set using the Benjamini-Hochberg procedure. 203 
b Linear mixed effect model comparing the scores of the 3 groups over time. A false discovery rate of 5% was set using 204 
the Benjamini-Hochberg procedure. P1 = GD vs HC, P2 = Het GBA vs HC, P3 = GD vs Het GBA 205 
* Significant result206 
HC  Het GBA GD P (between b)
P1 P2 P3 
UPSIT Baseline 35.15 ( 0.50) 31.00 ( 1.38) 32.39 ( 0.91) 
Follow-up  31.54 ( 1.17) 30.29 ( 1.25) 31.00 ( 1.37) 
N 13 14 23 
P (within a) 0.013* 0.358 0.312 <0.001* <0.001* 0.700
UMSARS 
reduced 
Baseline 0 0.25 ( 0.14) 0.39 ( 0.14) 
Follow-up 1.21( 0.37) 2.13 ( 0.44) 1.90 ( 0.34) 
N 14 16 31 
P (within a) 0.004* 0.001* <0.001* 0.019 0.066 0.568
RBDsq Baseline 0.42 ( 0.22) 0.20 ( 0.2) 0.55 ( 0.32) 
Follow-up 1.50 ( 0.63) 3.00 ( 0.74) 2.77 ( 0.68) 
N 12 15 22 
P (within a) 0.117 <0.001* <0.001* 0.183 0.935 0.152
MoCA Baseline 26.56 ( 0.50) 25.81 ( 0.7) 26.40 ( 0.40) 
Follow-up 28.06 (0.42) 27.19 ( 0.46) 26.83 ( 0.52) 
N 16 16 30 
P (within a) 0.019* 0.068 0.141 0.006* 0.086 0.316
MDS-
UPDRS III 
Baseline 0.44 ( 0.27) 0.94 ( 0.46) 2.81 ( 1.08) 
Follow-up 2.06 ( 0.77) 3.31 ( 1.05) 7.52 ( 2.40) 
N 16 16 31 
P (within a) 0.048 0.010* <0.001* 0.001* 0.001* 0.209
BDI Baseline 0.00 0.00 2.12 ( 1.28) 
Follow-up 3.00 ( 1.48) 5.67 ( 1.19) 10.00 ( 2.16) 
N 7 9 26 
P (within a) 0.031* 0.007* 0.001* 0.198 0.993 0.149
11 
UPSIT at baseline predicts a greater deterioration in the clinical scores at 6 years in GBA1 positive 207 
individuals 208 
Among the Het GBA and GD groups (pooled together), a baseline UPSIT score of less than or equal to 23 209 
was associated with a subsequent greater deterioration in UPSIT (-5.0 points vs -0.7 points, p=0.02), MoCA 210 
(-2.0 points vs +1.5 points, p=0.02), MDS-UPDRS III  (10.0 points vs 1.9 points, p=0.01) and BDI (17.0 points 211 
vs 4.6 points, p=0.01). Results are reported in table 4 and figure 2. No difference was observed for RBDsq 212 
and reduced UMSARS scores. None of the HC subjects had a baseline UPSIT score less than or equal to 23 213 
so no comparison with HC was performed (Table 4, Figure 2). 214 
TAB. 4 – UPSIT at baseline and 6-year change in clinical markers in pooled GBA Het and GD groups  215 
UPSIT > 23 UPSIT <= 23  p-value (FP test) a
UPSIT -0.7 ± 0.5 (33) -5.0 ± 3.1 (4) 0.020 *
UMSARS 1.4 ± 0.2 (40) 2.8 ± 1.0 (4) 0.080 
RBDsq 2.6 ± 0.5 (32) 1.7 ± 0.3 (3) 0.727 
MoCA 1.5 ± 0.4 (40) -2 ± 1.7 (3) 0.022 *
MDS-UPDRS III 1.9 ± 0.8 (40) 10.0 ± 5.3 (4) 0.010 *
BDI 4.6 ± 1.3 (29) 17 ± 6.1 (3) 0.012 *
Difference between 6-year follow up and baseline measurements. Data are reported as mean ± standard error 216 
(number of subject).  217 
a Nonparametric two-sample Fisher-Pitman permutation test.  The statistic used is the difference in means of two 218 
samples. A false discovery rate of 5% was set using the Benjamini-Hochberg procedure. 219 
*Significant result. 220 
GCase activity in GBA1 mutation carriers’ leucocytes  221 
We collected blood samples from 56 subjects (14 HC, 16 GBA Het, 26 GD). GCase activity was significantly 222 
lower in both GD and Het GBA subjects compared to controls. The GD group also displayed a significantly 223 
lower GCase activity compared to the Het GBA group. Results are shown in Figure 3. . No significant 224 
correlation between clinical parameters and GCase activity was observed between the three groups. 225 
226 
227 
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DISCUSSION 228 
Although GBA1 mutations are recognised genetic risk factors for developing PD, both in the biallelic and in 229 
heterozygote carrier states[1,33], the underlying mechanisms that determine penetrance are incompletely 230 
understood. Hyposmia, cognitive dysfunction, autonomic dysfunction, RBD, and depression are recognised 231 
prodromal features of PD and they are prevalent among GBA1 positive individuals [17,34].  232 
In this study, we assessed GD, Het GBA carriers and a group of GBA1 mutation-negative controls for the 233 
presence of non-motor features and parkinsonian motor signs that could determine an increased risk of 234 
developing PD. We analyzed these individuals at baseline and after 6 years in order to evaluate the clinical 235 
progression of these features and therefore to identify potential clinical early markers of 236 
neurodegeneration.  237 
The main finding of our study is a clear biological effect of GBA1 mutations: Het GBA carriers and GD 238 
patients showed progressive worsening of scores in most of the clinical markers evaluated over the 6 years 239 
compared to HC. Moreover, at 6 years, some Het GBA carriers and the majority of GD subjects developed 240 
non-motor and motor symptoms and 1 GD subject developed PD. The major deterioration observed was 241 
for olfactory function, motor scores and cognitive functions.  242 
243 
After 6 years of follow-up, the HC group additionally showed a deterioration in some of the parameters 244 
(UPSIT, reduced UMSARS and BDI). This is particularly evident for olfaction, where the HC group had the 245 
largest difference of the three groups from baseline. However, both GD and Het GBA showed consistently 246 
worse scores compared to HC over the 6 years and the statistical analysis shows that this difference is 247 
significant for UPSIT, MDS-UPDRS III and MoCA.  248 
MoCA results require particular mention, as the HC group showed a statistically significant improvement 249 
(not reduction) at 6-years, the same slight improvement has been shown in the other groups although they 250 
did not reach the significance. The lack of efficacy in detecting a cognitive decline is probably attributable 251 
to a “training effect” as participants repeated the same test multiple times, and this may have limited our 252 
evaluation.  253 
13 
These findings are in line with the previous papers published by our group [19,20] and support the 254 
hypothesis that GBA1 mutations have a significant effect on the development of early clinical markers of 255 
neurodegeneration. In particular, the six year follow-up of our study confirms the deterioration of motor 256 
and non-motor features that were found in GBA1 positive individuals in the previous publications[19,20].   257 
Over the 6-year follow-up, only 1 GD patient developed clinically definite PD associated with cognitive 258 
impairment.  259 
Previous studies tried to quantify the risk of developing PD in GBA1 mutation carriers and they estimated 260 
this risk at 5-30% by the age of 80 [35]. Given that the mean age at recruitment in our study was relatively 261 
low (<65 years), this finding is not unexpected. Moreover, all subjects were recruited without any 262 
neurological symptom at baseline. This likely introduced a selection bias, excluding individuals with a higher 263 
risk of developing PD and thus reducing the numbers of converters. Nonetheless, some of the GBA1264 
mutation positive individuals showed significant motor and non-motor features at six years which, although 265 
not diagnostic for PD so far, might be suggestive of a progression toward a neurodegenerative disorder, 266 
such as PD or Lewy Body Dementia[36]. 267 
As an exploratory analysis, we sought to define clinical characteristics at baseline that could predict a worse 268 
outcome at 6 years. We found that a low baseline UPSIT score (severe microsmia) was a strong predictor 269 
for greater deterioration in motor and non-motor markers. Olfactory dysfunction is considered an early 270 
‘pre-clinical’ sign of PD in the general population. However, by assessing this prodromal feature (low UPSIT 271 
score) in a population that has a genetic predisposition to PD, we can amplify its strength in predicting the 272 
development of the disease. Of course, given the small numbers on which this particular analysis was 273 
carried out, it is mandatory to confirm our results on a bigger sample. 274 
At 6 years, we also analysed the GCase activity level in peripheral blood leukocytes of our cohort.  As 275 
expected, mean GCase enzymatic activity in GD was significantly lower compared to other groups while it 276 
was intermediate in Het GBA carriers.  GCase is a lysosomal enzyme that hydrolyzes glucosylceramide to 277 
glucose and ceramide. Reduced GCase enzymatic activity is reported in patients with PD and Lewy body 278 
dementia in brain autopsy studies [37] CSF, [38,39] leucocytes [40] and monocytes[41]  suggesting a lower 279 
GCase enzymatic activity in peripheral cells may be a potential early marker of PD[40,42]. Accordingly, we 280 
14 
explored whether clinical markers at 6 years correlated with GCase enzymatic activity among GBA Het and 281 
GD. No significant association was found between GCase activity and the clinical scales (UPSIT, reduced 282 
UMSARS, MDS-UPDRS III, MOCA, RBDsq and BDI).  Alcalay et al[40] tested the association between GCase 283 
enzymatic activity and PD severity and reported that in patients with idiopathic PD, higher GCase enzymatic 284 
activity was associated with longer disease duration and a milder disease course. No data are available on 285 
the association between GCase activity and parkinsonian clinical features in GBA Het carriers and further 286 
studies are needed to define this aspect.  287 
A limitation of our study is the lack of longitudinal measurement of GCase activity. It would be interesting 288 
to assess potential changes in GCase activity over time and correlate to disease progression. Furthermore, 289 
we acknowledge that the small sample size, as a consequence of the drop-out rate after 6 years, 290 
constitutes a limitation of this study and calls for validation of our results in an independent cohort. It is 291 
also possible that the participants that dropped out at follow-up were the most clinically impaired. This 292 
could introduce an attrition bias, where the GBA1 positive individuals with the higher risk of developing PD 293 
were lost at follow-up before the development of motor symptoms. Moreover, since the dropouts were all 294 
within the Het GBA and HC groups, a surveillance bias might explain, at least partially, the higher incidence 295 
of non-motor symptoms in the GD group compared to the other groups. In this regard, we did not find any 296 
significant difference in the baseline clinical scores of dropout participants (supplementary table 2). The 297 
longitudinal model we used also partially overcomes this problem by taking into account incomplete 298 
assessment from dropout participants, although this required treating as continuous variables that should 299 
ideally be treated as categorical, in particular the RBDsq. Finally, we defined the presence of RBD by using 300 
only the RBDsq. While this is considered a good screening tool, polysomnography is required to confirm the 301 
diagnosis of RBD. Nonetheless, our study includes a significant period of observation (6 years) in a unique 302 
cohort of GBA1 positive individuals carefully evaluated for the presence of prodromal features over time. 303 
We were able to confirm the biological effect of GBA1 mutations in determining clinical features suggestive 304 
of PD and we identified hyposmia as a predictive factor for deterioration in this population.  305 
306 
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Figures titles and legends 307 
308 
FIG. 1 – Evolution of clinical markers over 6 years 309 
310 
The graphs show the mean scores at baseline and at the 6-year follow-up for HC, Het GBA and GD subjects. 311 
HC= healthy controls Het GBA= heterozygotes GBA1 mutation carriers GD= Gaucher disease patients 312 
a Het GBA statistically different from HC 313 
b GD statistically different from HC  314 
*6-year score significantly different from baseline score 315 
316 
317 
FIG. 2 – UPSIT at baseline as predictor of worse clinical outcome at 6 years  318 
319 
The graphs show the mean difference between 6-year and baseline scores for GBA1 positive subjects (Het GBA and 320 
GD), stratified for baseline UPSIT (cutoff <=23). A p-value <0.05 is considered significant.  321 
* Significant difference 322 
323 
324 
FIG. 3 – GCase activity level in leucocytes in the 3 groups325 
Box plots of GCase activity for the 3 groups. Group comparison performed with Kruskal-Wallis followed by post-hoc 326 
analysis with Dunn's Pairwise Comparison test. After Bonferroni correction, a p-value of less than 0.017 was considered 327 
significant. HC range:7.7 - 17.47; Het GBA range: 4.01 - 12.76; GD range: 0.26- 4.48.   HC vs GBA Het p< 0.0001; HC vs 328 
GD p < 0.0001; GBA Het vs GD p< 0.0001  329 
 *Significant difference.  330 
331 
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